Open an account

NewcelX AG

NCEL · NASDAQ

$2.61−$0.02 (−0.76%)TodayMarket closed ·
Prev close $2.63

About NCEL

NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The firm offers products like Quilience, which is a clinical-stage pharmaceutical compound. The company aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The firm also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The firm is a publicly traded company, listing on the NASDAQ.

Employees
1
Headquarters
Zurich, Zuerich
Listed
Jan 29, 2021
Sector
Health Care
Industry
Biotechnology
Website
nlspharma.com

NCEL key statistics

Market cap
14.05M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
6.04K
Volume
9.41K
Open price
$2.49
High today
$3.00
Low today
$2.55
52 Week high
$17.25
52 Week low
$0.76

NewcelX AG (NCEL) at a glance

As of Oct 20, 2026, NewcelX AG (NCEL) shares are priced at $2.61, giving the company a market cap of 14.05M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.55 and $3.00. The current price is 2.4% above the day's low and 13.0% below its high.

Volume so far is 9.41K shares, above the average of 6.04K shares a day.

Over the past year NewcelX AG has ranged from $0.76 to $17.25, and now sits 11% of the way up that range.

The average analyst price target is $23.46, 798.9% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $23.46
Low
$23.23
Now
$2.61
High
$24.15

NCEL news

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releasePRNewswire

    The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy

  • NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy

  • Press releaseGlobe Newswire

    NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releasePRNewswire

    NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

  • Press releasePRNewswire

    NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy

  • Press releasePRNewswire

    NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences

Similar companies

Companies in the same industry as NewcelX AG

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.